Related Experiment Video
Updated: Jun 18, 2025
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Non-research payments to board-certified cardiologists from pharmaceutical industry in Japan from 2016 to 2019: a
Anju Murayama1, Kenichi Higuchi2, Yuki Senoo3
1School of Medicine, Tohoku University, Sendai, Miyagi, Japan anju.murayama.s8@dc.tohoku.ac.jp.
Objectives:
To evaluate the extent and trends of personal payments from pharmaceutical companies to cardiologists board-certified by the Japanese Circulation Society.
Design:
A retrospective analysis study using data from a publicly available database.
Setting:
The study focused on payments to cardiologists in Japan.
Participants:
All 15 048 cardiologists who were board-certified by the Japanese Circulation Society as of 2021.
Primary And Secondary Outcome Measures:
The primary outcome was the extent of personal payments to cardiologists in 2016-19. Secondary outcomes included the analysis of trends in these payments over the same period.
Results:
Of all 15 048 board-certified cardiologists, 9858 (65.5%) received personal payments totaling $112 934 503 entailing 165 013 transactions in 2016-19. The median payment per cardiologist was $2947 (IQR, $1022-$8787), with a mean of $11 456 (SD, $35 876). The Gini Index was 0.840, indicating a high concentration of payments to a small number of cardiologists. The top 1%, 5% and 10% of cardiologists received 31.6%, 59.4% and 73.5% of all payments, respectively. There were no significant trends in the number of cardiologists receiving payments or number of payments per cardiologist during the study period.
Conclusions:
More than 65% of Japanese cardiologists received personal payments from pharmaceutical companies over the 4-year study period. Although the payment amount was relatively small for the majority of cardiologists, a small number of cardiologists received the vast majority of the payments.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
11:00Reliable Acquisition of Electroencephalography Data during Simultaneous Electroencephalography and Functional MRI
Published on: March 19, 2021
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:22Heart Failure Drugs: β-Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers